Analytical Data
-
Gene name
CYP2C8
- Application
-
Alternative Names
CYPIIC8 (Cytochrome P450 IIC2) (Cytochrome P450 MP-12) (Cytochrome P450 MP-20) (Cytochrome P450 form 1) (S-mephenytoin 4-hydroxylase)
-
Species
Human
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P10632
-
Expression Region
27-490aa
-
Molecular Weight
60.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CYP2C8, a member of the cytochrome P450 family, plays a crucial role in drug metabolism and is primarily involved in the oxidation of various xenobiotics and endogenous compounds. Understanding CYP2C8 function is essential for predicting drug interactions, metabolite formation, and individual variability in drug responses. Genetic polymorphisms and environmental factors can significantly affect CYP2C8 activity, leading to altered pharmacokinetics and increased risk of adverse drug reactions. Research has focused on the recombinant expression of CYP2C8 to facilitate detailed studies of its enzymatic properties, substrate specificity, and interaction with inhibitors or inducers. Advances in recombinant protein technology have enabled the production of CYP2C8 in heterologous systems, providing insights into its structural and functional aspects. Furthermore, studies on CYP2C8 have implications in personalized medicine, as understanding its variability can aid in optimizing drug dosing and minimizing toxicity for patients with different genetic backgrounds. Overall, the investigation of CYP2C8 recombinant protein is vital for enhancing the understanding of metabolic pathways and improving the safety and efficacy of therapeutic interventions.
